Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Research suggests relapses can lead to harm, reduce the quality of life, and have a heavy economic impact on patients with ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the ...

Are family-based interventions effective and safe for people with schizophrenia and their families, compared with standard care?

Art therapy can help individuals express thoughts and feelings without relying solely on words, providing a valuable outlet ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

The distress from voices heard by schizophrenia patients were lessened when treated using digital avatars, new study showed.

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

Families are left struggling as the consequences of a 2020 law passed by the Colorado Legislature are preventing law ...

Studying synapses in live human brains is crucial for understanding many psychiatric disorders. Now, using positron emission ...

Even though psychiatric disorders such as schizophrenia ... and diagnostics based on synaptic function, improving treatment precision and outcomes." With much luck, accurate diagnosis and effective ...